With the federal repositioning of FDA-approved cannabinoid products and state-licensed medical cannabis from Schedule I to a Schedule III drug, federal regulators have recognized the medical value of cannabinoid medicine.
Rescheduling cannabis to Schedule III is a long-overdue federal recognition that cannabinoid medicine is real, that patient need is real, and that the clinicians who have spent careers serving those patients deserve to practice with legitimate scientific and federal regulatory validation.
ACS stands ready to work with federal partners, researchers, and policymakers to ensure that rescheduling translates into expanded clinical access, rigorous science, and meaningful relief for the patients.
For support, guidance, or resources such as our CME course, please reach out to [email protected] or visit www.cannaspecialists.org